Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Valeo Pharmainc (VPH.CN)

Valeo Pharmainc (VPH.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 48,202
  • Shares Outstanding, K 66,030
  • Annual Sales, $ 7,470 K
  • Annual Income, $ -4,761 K
  • 60-Month Beta N/A
  • Price/Sales 5.37
  • Price/Cash Flow N/A
  • Price/Book 31.24
Trade VPH.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.10
  • Most Recent Earnings -0.03 on 04/30/21
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.570 +24.56%
on 07/22/21
0.950 -25.26%
on 06/30/21
-0.160 (-18.39%)
since 06/25/21
3-Month
0.570 +24.56%
on 07/22/21
1.220 -41.80%
on 05/05/21
-0.500 (-41.32%)
since 04/27/21
52-Week
0.570 +24.56%
on 07/22/21
1.860 -61.83%
on 07/29/20
-0.800 (-52.98%)
since 07/27/20

Most Recent Stories

More News
Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™

Amongst Canadian provinces, territories and governmental agencies presently publicly covering Redesca™ and Redesca HP™ for reimbursement are, , , , , , , , Non Insured Health Benefits for registered...

VPH.CN : 0.710 (-2.74%)
VPHIF : 0.5787 (+6.03%)
Valeo Pharma Ceo Interview on RICH TV LIVE

(via TheNewswire)

VPHIF : 0.5787 (+6.03%)
VPH.CN : 0.710 (-2.74%)
Valeo Pharma Reports its Second Quarter 2021 Results and Highlights

COMTEX_389125922/2669/2021-06-29T19:55:08

VPH.CN : 0.710 (-2.74%)
VPHIF : 0.5787 (+6.03%)
Valeo Pharma Closes $11.5 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

VPH.CN : 0.710 (-2.74%)
VPHIF : 0.5787 (+6.03%)
Valeo Pharma to Report Second Quarter 2021 Results and Hold Investors Conference Call / Webcast

/PRNewswire/ - . (CSE:VPH) (OTCQB: VPHIF) (FSE:VP2) ("" or the ""), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended...

VPH.CN : 0.710 (-2.74%)
VPHIF : 0.5787 (+6.03%)
Valeo Pharma Announces Commercial Launch of Enerzairœ Breezhalerœ and Atecturaœ Breezhalerœ

"The commercial launch of Enerzair Breezhaler and Atectura Breezhaler is a key milestone for Valeo. It marks the debut of the Company's commercial efforts in the Canadian asthma market, one of largest...

NVS : 91.32 (+0.40%)
VPH.CN : 0.710 (-2.74%)
VPHIF : 0.5787 (+6.03%)
Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzairœ Breezhalerœ and Atecturaœ Breezhalerœ

Enerzair Breezhaler and Atectura Breezhaler are two new innovative asthma therapies which have been approved for use in Canada. 

VPHIF : 0.5787 (+6.03%)
VPH.CN : 0.710 (-2.74%)
Valeo Pharma Projecting Record Revenues for Second Quarter 2021

"Our second quarter showed a sharp increase in both sales and margins and promises to be the highest revenue quarter in the Company's history following the national launch of Redesca® in the last weeks...

VPH.CN : 0.710 (-2.74%)
VPHIF : 0.5787 (+6.03%)
Valeo Pharma Joins Innovative Medecines Canada

COMTEX_386745497/2669/2021-05-17T07:00:59

VPH.CN : 0.710 (-2.74%)
VPHIF : 0.5787 (+6.03%)
Valeo Pharma Announces Voting Results of its 2021 Annual General and Special Meeting of Shareholders

Valeo Pharma Announces Voting Results of its 2021 Annual General and Special Meeting of Shareholders

VPH.CN : 0.710 (-2.74%)
VPHIF : 0.5787 (+6.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.770
2nd Resistance Point 0.750
1st Resistance Point 0.730
Last Price 0.710
1st Support Level 0.690
2nd Support Level 0.670
3rd Support Level 0.650

See More

52-Week High 1.860
Fibonacci 61.8% 1.367
Fibonacci 50% 1.215
Fibonacci 38.2% 1.063
Last Price 0.710
52-Week Low 0.570

See More

Business Summary

Valeo Pharma Inc a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its products include Benztropine, Synacthen,...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar